Virbez 300

Irbesartan

Essential HTN in adults. Renal disease in adults w/ HTN & type 2 DM as part of an antihypertensive medicinal product regimen.

150 mg once daily as initial & maintenance dose. May be increased to 300 mg, or add other antihypertensive agents if insufficiently controlled. Hypertensive type 2 diabetic patient Initially 150 mg once daily & titrated up to 300 mg once daily as preferred maintenance dose for treatment of renal disease. Patient undergoing haemodialysis Consider lower starting dose of 75 mg.

May be taken with or without food.

Hypersensitivity. 2nd & 3rd trimester of pregnancy.

Symptomatic hypotension. Correct vol &/or Na depletion prior to administration. Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Renal impairment & kidney transplantation. Periodic monitoring of K levels & creatinine serum levels in patients w/ impaired renal function. Hypertensive patients w/ type 2 diabetes & renal disease. Close monitoring of serum K in patients at risk of hyperkalaemia (eg, those w/ presence of renal impairment, overt proteinuria due to diabetic renal disease, &/or heart failure). Not recommended to be combined w/ lithium. Patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Not recommended in patients w/ primary aldosteronism. Patients w/ severe CHF or underlying renal disease, including renal artery stenosis. Excessive BP decrease in patients w/ ischemic cardiopathy or ischemic CV disease could result in MI or stroke. Black people. Contains lactose. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Severe hepatic impairment. Pregnancy. Childn <18 yr. Elderly.

Hyperkalaemia in diabetic patients. Dizziness, orthostatic dizziness; orthostatic hypotension; nausea/vomiting; musculoskeletal pain; fatigue; significant increase in plasma creatine kinase, decrease in Hb.

May increase hypotensive effects w/ other antihypertensive agents. May result in vol depletion & risk of hypotension w/ high dose diuretics when initiating therapy. May lead to increases in serum K w/ K-sparing diuretics, K supplements, salt substitutes containing K or other medicinal products that may increase serum K levels (eg, heparin). Reversible increases in serum conc & toxicity of lithium. Attenuation of the antihypertensive effect & increased risk of worsening of renal function, including possible acute renal failure, & increase in serum K especially in patients w/ poor pre-existing renal function w/ NSAIDs (ie, selective COX-2 inhibitors, ASA >3 g/day & nonselective NSAIDs).

Angiotensin II Antagonists

C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx